LAWRENCE, Mass., Aug. 6, 2015 /PRNewswire/ -- This summer,
NxStage Medical, Inc. (Nasdaq: NXTM), a leading
manufacturer of dialysis products, is celebrating the
10th year anniversary of the Food and Drug
Administration's (FDA) clearance of the first and only portable
home hemodialysis (HHD) system, the NxStage® System One™. In
connection with the anniversary, NxStage unveiled details of new
innovations from its robust pipeline including its next generation
hemodialysis system, peritoneal dialysis (PD) system and next
generation critical care system during its second quarter of 2015
financial results conference call this morning. In addition,
NxStage announced that it expects to begin by launching its next
generation hemodialysis system later next year.
"Over the last decade, NxStage's model of innovation has yielded
transformational technologies, including the System One, our
dialysate preparation system, and a rich portfolio of integrated
offerings and capabilities," stated Jeffrey
H. Burbank, Founder and Chief Executive Officer of NxStage.
"We're proud to have a portfolio that includes many of the
industry's 'firsts' in terms of technology and clearances that are
having a wonderful impact on patient lives and advancing the
standard of renal care."
"As a clinician, I've seen that the life-changing benefits of
HHD with the System One are truly remarkable," said Renal Nurse
Practitioner Lisa Koester of Barnes Jewish Dialysis Center in
St. Louis, Missouri. "Because of
this breakthrough technology, patients are able to get back to
work, family and a more normal life."
Burbank continued, "Our established track record of innovation
is enabling strong growth, market expansion, customer
diversification, and solid operating performance across our
business, in addition to laying the groundwork for much more. I'm
excited to deliver new breakthrough technologies for HHD, PD,
critical care, as well as traditional three times weekly in-center
therapy. These innovations are designed to give patients even
more flexibility in meeting their clinical and lifestyle needs, as
well as provide economic advantages to our customers. We expect
these innovations to significantly expand our addressable market,
from an estimated $1 billion to $5
billion in total, and fuel our long-term growth."
To learn more about NxStage's history of innovation, visit
Our History of Innovation for a
graphic timeline highlighting the Company's milestone
clearances.
NxStage will also host a conference call today at 9:00 a.m. Eastern Time to discuss its second
quarter financial results and its technology pipeline. To
listen to the conference call, please dial 877-392-9886 (domestic)
or 707-287-9329 (international). The call will also be
webcast LIVE and can be accessed via the investor relations section
of the Company's website at http://ir.nxstage.com. A replay
of the conference call will be available through August 14, 2015 by dialing 855-859-2056
(domestic) or 404-537-3406 (international) and referencing
conference ID 77465339. An online archive of the conference
call can be accessed via the investor relations section of the
Company's website at http://ir.nxstage.com.
For more information about the System One, home hemodialysis or
home nocturnal hemodialysis, please visit www.nxstage.com.
Despite the health benefits that home hemodialysis may
provide to those with chronic kidney disease, this form of therapy
is not for everyone. The reported benefits of home hemodialysis may
not be experienced by all patients. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if
needed.
About the NxStage System One
The NxStage System One
is the first and only portable hemodialysis machine cleared
specifically by the U.S. Food & Drug Administration (FDA) for
home hemodialysis and home nocturnal hemodialysis. Its simplicity
and revolutionary size (just over a foot tall) are intended to
allow convenient use in patients' homes and give patients the
freedom to travel with their therapy. When combined with the
NxStage Pureflow SL Dialysis Preparation System, patients are able
to further simplify, using ordinary tap water to create dialysis
fluid. Unlike conventional hemodialysis systems, the System One
requires no special infrastructure to operate. Under the guidance
of their physician, patients can use the NxStage System One, with
their trained partners, where, how and when it best meets their
needs, including while they are sleeping - at home or on vacation
and at a medically appropriate treatment frequency. The System One
is also used to provide a range of flexible therapy options in more
traditional care settings such as hospitals and dialysis centers.
Its safety and efficacy have been demonstrated by experience with
more than 10 million treatments with thousands of patients around
the world. www.nxstage.com.
About NxStage Medical
NxStage Medical
Inc. (Nasdaq: NXTM) is a medical device company,
headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets
innovative products for the treatment of ESRD and acute kidney
failure. For more information on NxStage and its products, please
visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including its most recent quarterly or annual
report.
NxStage is under no obligation to (and expressly disclaims any
such obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or
otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.commailto:ksheppard@nxstage.com
Tel: (978) 332-5923
Logo - http://photos.prnewswire.com/prnh/20150624/225341
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-celebrates-10th-anniversary-of-the-revolutionary-system-one-unveils-robust-pipeline-and-launch-plans-300124544.html
SOURCE NxStage Medical, Inc.